{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T21:50:12Z","timestamp":1774475412776,"version":"3.50.1"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1097\/ftd.0b013e3181c13a30","type":"journal-article","created":{"date-parts":[[2010,1,22]],"date-time":"2010-01-22T08:35:39Z","timestamp":1264149339000},"page":"19-29","source":"Crossref","is-referenced-by-count":29,"title":["Does Valproic Acid Warrant Therapeutic Drug Monitoring in Bipolar Affective Disorder?"],"prefix":"10.1097","volume":"32","author":[{"given":"Jennifer","family":"Haymond","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary H H","family":"Ensom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210129","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00003088-200038040-00004","article-title":"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.","volume":"38","author":"Wilbur","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"R3-4-20210129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14737175.7.1.9","article-title":"Spectrum of effectiveness of valproate in neuropsychiatry.","volume":"7","author":"Bowden","year":"2007","journal-title":"Expert Rev Neurother"},{"issue":"Suppl 3","key":"R8-4-20210129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1399-5618.2005.00219.x","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.","volume":"7","author":"Yatham","year":"2005","journal-title":"Bipolar Disord"},{"key":"R9-4-20210129","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/01.WNF.0000228209.69524.E8","article-title":"Therapeutic monitoring of valproate in psychiatry: how far have we progressed?","volume":"29","author":"Fleming","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"R10-4-20210129","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2165\/00023210-200721120-00005","article-title":"Valproate use in children and adolescents with bipolar disorder.","volume":"21","author":"Azorin","year":"2007","journal-title":"CNS Drugs"},{"key":"R11-4-20210129","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/00003088-199834040-00001","article-title":"Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes?","volume":"34","author":"Ensom","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"R12-4-20210129","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/026988110101500305","article-title":"Pharmacokinetics of valproic acid in patients with bipolar disorder.","volume":"15","author":"Vasudev","year":"2001","journal-title":"J Psychopharmacol"},{"issue":"Suppl 1","key":"R13-4-20210129","doi-asserted-by":"crossref","first-page":"57S","DOI":"10.1097\/00004714-199202001-00009","article-title":"Algorithm for patient management of acute manic states: lithium, valproate, or carbamazepine?","volume":"12","author":"Gerner","year":"1992","journal-title":"J Clin Psychopharmacol"},{"key":"R16-4-20210129","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1399-5618.2006.00432.x","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.","volume":"8","author":"Yatham","year":"2006","journal-title":"Bipolar Disord"},{"key":"R18-4-20210129","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archpsyc.57.5.481","article-title":"A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder.","volume":"57","author":"Bowden","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R20-4-20210129","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0378-4347(95)00273-8","article-title":"Solid-phase microextraction for the determination of the free concentration of valproic acid in human plasma by capillary gas chromatography.","volume":"637","author":"Krogh","year":"1995","journal-title":"J Chromatogr B"},{"key":"R21-4-20210129","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jchromb.2005.11.028","article-title":"Development and validation of a sensitive assay of valproic acid in human plasma by high-performance liquid chromatography without prior derivatization.","volume":"830","author":"Amini","year":"2006","journal-title":"J Chromatogr B"},{"key":"R22-4-20210129","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/000456328001700605","article-title":"Valproic acid estimation by enzyme immunoassay.","volume":"17","author":"Elyas","year":"1980","journal-title":"Ann Clin Biochem"},{"key":"R23-4-20210129","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/00007691-200012000-00011","article-title":"Assessment of drug concentrations in tears in therapeutic drug monitoring: I. Determination of valproic acid in tears by gas chromatography\/mass spectrometry with EC\/NCI mode.","volume":"22","author":"Nakajima","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R24-4-20210129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1528-1157.1982.tb05049.x","article-title":"The free fraction of valproic acid in tears, saliva, and cerebrospinal fluid.","volume":"23","author":"Monaco","year":"1982","journal-title":"Epilepsia"},{"key":"R25-4-20210129","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2165\/00003495-199447020-00008","article-title":"Vaplproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy.","volume":"47","author":"Davis","year":"1994","journal-title":"Drugs"},{"key":"R28-4-20210129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s002130000380","article-title":"Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder.","volume":"150","author":"Vasudev","year":"2000","journal-title":"Psychopharmacology"},{"key":"R29-4-20210129","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00004714-200004000-00031","article-title":"Correlation of valproate plasma concentrations and dose in bipolar affective disorder [letter].","volume":"20","author":"Perry","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R30-4-20210129","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/ajp.153.6.765","article-title":"Relation of serum valproate concentration to response in mania.","volume":"153","author":"Bowden","year":"1996","journal-title":"Am J Psychiatry"},{"key":"R31-4-20210129","first-page":"372","article-title":"Evaluation of the valproic acid assay on the Bayer Technicon Immuno 1 System.","volume":"30","author":"Martel","year":"1997","journal-title":"Clin Biochem"},{"key":"R32-4-20210129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/clinchem\/27.1.169","article-title":"Evaluation of a new valproic acid enzyme immunoassay and comparison with a capillary gas-chromatographic method.","volume":"27","author":"Braun","year":"1981","journal-title":"Clin Chem"},{"key":"R33-4-20210129","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0009-9120(81)90772-4","article-title":"Comparison of gas-liquid chromatography and emit assay for serum valproic acid.","volume":"14","author":"Leroux","year":"1981","journal-title":"Clin Biochem"},{"key":"R36-4-20210129","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/088307380001501105","article-title":"Anticonvulsant blood levels: historical review with a pediatric focus.","volume":"15","author":"Snodgrass","year":"2000","journal-title":"J Child Neurol"},{"key":"R39-4-20210129","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJM199601183340308","article-title":"Antiepileptic drugs.","volume":"334","author":"Brodie","year":"1996","journal-title":"N Engl J Med"},{"key":"R41-4-20210129","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1528-1157.2000.tb00144.x","article-title":"A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy.","volume":"41","author":"Jannuzzi","year":"2000","journal-title":"Epilepsia"},{"key":"R42-4-20210129","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity, and sensitivity.","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"R44-4-20210129","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.1365-2710.1999.00250.x","article-title":"Measuring mania and critical appraisal of rating scales.","volume":"24","author":"Poolsup","year":"1999","journal-title":"J Clin Pharm Ther"},{"key":"R45-4-20210129","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archpsyc.1991.01810250064008","article-title":"Valproate in the treatment of acute mania: a placebo-controlled study.","volume":"48","author":"Pope","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"R46-4-20210129","first-page":"127","article-title":"Correlates of antimanic response to valproate.","volume":"27","author":"McElroy","year":"1991","journal-title":"Psychopharmacol Bull"},{"key":"R47-4-20210129","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.1994.03510360044034","article-title":"Efficacy of divalproex vs lithium and placebo in the treatment of mania.","volume":"271","author":"Bowden","year":"1994","journal-title":"JAMA"},{"key":"R48-4-20210129","doi-asserted-by":"crossref","first-page":"815","DOI":"10.4088\/JCP.v60n1202","article-title":"Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients.","volume":"60","author":"Hirschfeld","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R49-4-20210129","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/13651500500305622","article-title":"Relationship between serum valproate and lithium levels and efficacy and tolerability in bipolar maintenance therapy.","volume":"9","author":"Keck","year":"2005","journal-title":"Int J Psychiatry Clin Pract"},{"key":"R50-4-20210129","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1176\/appi.ajp.159.6.1011","article-title":"Olanzapine versus divalproex in the treatment of acute mania.","volume":"159","author":"Tohen","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R51-4-20210129","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1176\/appi.ajp.163.2.272","article-title":"Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania.","volume":"163","author":"Allen","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R52-4-20210129","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/00003088-200140050-00001","article-title":"Concentration-controlled or effect-controlled trials.","volume":"40","author":"Grahnen","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"R53-4-20210129","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00007691-198507030-00009","article-title":"Chronic valproic acid therapy and incidence of increases in venous plasma ammonia.","volume":"7","author":"Haidukewych","year":"1985","journal-title":"Ther Drug Monit"},{"key":"R54-4-20210129","first-page":"100","article-title":"Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs.","volume":"22","author":"Ratnaike","year":"1986","journal-title":"Br J Clin Pharmacol"},{"key":"R55-4-20210129","first-page":"663","article-title":"Blood ammonia level during valproic acid therapy.","volume":"40","author":"Kugoh","year":"1986","journal-title":"Jpn J Psychiatry Neurol"},{"key":"R56-4-20210129","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/YIC.0b013e3281c61b28","article-title":"Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting.","volume":"22","author":"Dealberto","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"R58-4-20210129","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/j.1552-4604.1992.tb03889.x","article-title":"Circadian changes of valproate kinetics depending on meal condition in humans.","volume":"32","author":"Ohdo","year":"1992","journal-title":"J Clin Pharmacol"},{"key":"R59-4-20210129","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2710.1995.tb00651.x","article-title":"Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy.","volume":"20","author":"Gidal","year":"1995","journal-title":"J Clin Pharm Ther"},{"key":"R60-4-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(25)06653-0","article-title":"Clearance approaches in pharmacology.","volume":"39","author":"Wilkinson","year":"1987","journal-title":"Pharmacol Rev"},{"key":"R61-4-20210129","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/clpt.1985.116","article-title":"Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults.","volume":"37","author":"Bauer","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"R62-4-20210129","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/phrs.1998.0424","article-title":"Spotlight on the continual applicability of routine plasma monitoring antiepileptic drugs in the treatment of epilepsy.","volume":"39","author":"El Desoky","year":"1999","journal-title":"Pharmacol Res"},{"key":"R63-4-20210129","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1176\/appi.ajp.159.11.1927","article-title":"Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization.","volume":"159","author":"Scott","year":"2002","journal-title":"Am J Psychiatry"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3181c13a30","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T22:37:55Z","timestamp":1739745475000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201002000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181c13a30","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}